These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 30450823)

  • 21. Role of glial cell line-derived neurotrophic factor in the pathogenesis and treatment of mood disorders.
    Tsybko AS; Ilchibaeva TV; Popova NK
    Rev Neurosci; 2017 Apr; 28(3):219-233. PubMed ID: 28099138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of berberine on bone mineral density in SAMP6 as a senile osteoporosis model.
    Li H; Miyahara T; Tezuka Y; Tran QL; Seto H; Kadota S
    Biol Pharm Bull; 2003 Jan; 26(1):110-1. PubMed ID: 12520186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapy of mood disorders.
    Thase ME; Denko T
    Annu Rev Clin Psychol; 2008; 4():53-91. PubMed ID: 18370614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
    DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
    Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of berberine on hippocampal neuronal damage and matrix metalloproteinase-9 activity following transient global cerebral ischemia.
    Hong JS; Chu YK; Lee H; Ahn BH; Park JH; Kim MJ; Lee S; Ryoo HS; Jang JH; Lee SR; Park JW
    J Neurosci Res; 2012 Feb; 90(2):489-97. PubMed ID: 22052603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacological characterization and mechanisms of the novel antidepressive- and/or anxiolytic-like substances identified from Perillae Herba].
    Tsuji M; Miyagawa K; Takeuchi T; Takeda H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Aug; 28(4):159-67. PubMed ID: 18800619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variability in Potency Among Commercial Preparations of Berberine.
    Funk RS; Singh RK; Winefield RD; Kandel SE; Ruisinger JF; Moriarty PM; Backes JM
    J Diet Suppl; 2018 May; 15(3):343-351. PubMed ID: 28792254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paroxetine treatment of mood and anxiety disorders in children and adolescents.
    Wagner KD
    Psychopharmacol Bull; 2003; 37 Suppl 1():167-75. PubMed ID: 14566209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Duality of Antidepressants and Neuroprotectants.
    Tizabi Y
    Neurotox Res; 2016 Jul; 30(1):1-13. PubMed ID: 26613895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early risk factors for adult bipolar disorder in adolescents with mood disorders: a 15-year follow-up of a community sample.
    Päären A; Bohman H; von Knorring L; Olsson G; von Knorring AL; Jonsson U
    BMC Psychiatry; 2014 Dec; 14():363. PubMed ID: 25539591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Review on the Neuroprotective Effect of Berberine against Chemotherapy- induced Cognitive Impairment.
    Sahu K; Singh S; Devi B; Singh C; Singh A
    Curr Drug Targets; 2022; 23(9):913-923. PubMed ID: 35240956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Therapeutic Approach for the Management of Mood Disorders: In Vivo and In Vitro Effect of a Combination of L-Theanine,
    Borgonetti V; Governa P; Biagi M; Galeotti N
    Nutrients; 2020 Jun; 12(6):. PubMed ID: 32560413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Berberine and Its Role in Chronic Disease.
    Cicero AF; Baggioni A
    Adv Exp Med Biol; 2016; 928():27-45. PubMed ID: 27671811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botanicals for mood disorders with a focus on epilepsy.
    Ketcha Wanda GJ; Ngitedem SG; Njamen D
    Epilepsy Behav; 2015 Nov; 52(Pt B):319-28. PubMed ID: 26409901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Galanin receptor antagonists : a potential novel pharmacological treatment for mood disorders.
    Ogren SO; Kuteeva E; Hökfelt T; Kehr J
    CNS Drugs; 2006; 20(8):633-54. PubMed ID: 16863269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statins: Neurobiological underpinnings and mechanisms in mood disorders.
    Walker AJ; Kim Y; Borissiouk I; Rehder R; Dodd S; Morris G; Nierenberg AA; Maes M; Fernandes BS; Dean OM; Williams LJ; Eyre HA; Kim SW; Zoungas S; Carvalho AF; Berk M
    Neurosci Biobehav Rev; 2021 Sep; 128():693-708. PubMed ID: 34265321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Berberine up-regulates the BDNF expression in hippocampus and attenuates corticosterone-induced depressive-like behavior in mice.
    Shen JD; Ma LG; Hu CY; Pei YY; Jin SL; Fang XY; Li YC
    Neurosci Lett; 2016 Feb; 614():77-82. PubMed ID: 26773864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critical role of brain-derived neurotrophic factor in mood disorders.
    Hashimoto K; Shimizu E; Iyo M
    Brain Res Brain Res Rev; 2004 May; 45(2):104-14. PubMed ID: 15145621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The medicinal plant goldenseal is a natural LDL-lowering agent with multiple bioactive components and new action mechanisms.
    Abidi P; Chen W; Kraemer FB; Li H; Liu J
    J Lipid Res; 2006 Oct; 47(10):2134-47. PubMed ID: 16885565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest.
    Kim JB; Yu JH; Ko E; Lee KW; Song AK; Park SY; Shin I; Han W; Noh DY
    Phytomedicine; 2010 May; 17(6):436-40. PubMed ID: 19800775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.